Advertisement
Journal of Clinical Oncology  
Search for:
Limit by:
  Browse by Subject or Issue
Home Search or Browse JCO My JCO Subscriptions Customer Service Site Map

Originally published as JCO Early Release 10.1200/JCO.2002.11.076 on April 22 2002

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Purchase Article
Right arrow View Shopping Cart
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a colleague
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Save to my personal folders
Right arrow Download to citation manager
Right arrowRights & Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Witzig, T. E.
Right arrow Articles by White, C. A.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Witzig, T. E.
Right arrow Articles by White, C. A.
Social Bookmarking
Add to CiteULike   Add to Complore   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Facebook   Add to Reddit   Add to Technorati   Add to Twitter  
What's this?
Journal of Clinical Oncology, Vol 20, Issue 10 (May), 2002: 2453-2463
© 2002 American Society for Clinical Oncology

Randomized Controlled Trial of Yttrium-90–Labeled Ibritumomab Tiuxetan Radioimmunotherapy Versus Rituximab Immunotherapy for Patients With Relapsed or Refractory Low-Grade, Follicular, or Transformed B-Cell Non-Hodgkin’s Lymphoma

By Thomas E. Witzig, Leo I. Gordon, Fernando Cabanillas, Myron S. Czuczman, Christos Emmanouilides, Robin Joyce, Brad L. Pohlman, Nancy L. Bartlett, Gregory A. Wiseman, Norman Padre, Antonio J. Grillo-López, Pratik Multani, Christine A. White

From the Division of Internal Medicine and Hematology and Department of Radiology, Nuclear Medicine, Mayo Clinic and Mayo Foundation, Rochester, MN; Division of Hematology/Oncology and The Robert H. Lurie Comprehensive Cancer Center of Northwestern University, Chicago, IL; M.D. Anderson Cancer Center, Houston, TX; Roswell Park Cancer Center, Buffalo, NY; University of California Los Angeles Medical Center, Los Angeles, IDEC Pharmaceuticals Corporation, San Diego, and Clinical Research and Regulatory Strategy, Rancho Santa Fe, CA; Beth Israel Deaconess Medical Center, Boston, MA; The Cleveland Clinic Foundation, Cleveland, OH; and Washington University School of Medicine, St Louis, MO.

Address reprint requests to Thomas E. Witzig, MD, Mayo Clinic, 620 Stabile Building, Rochester, MN 55905; email: witzig{at}mayo.eduThis article was published online ahead of print at www.jco.org.

PURPOSE: Radioimmunotherapy combines biologic and radiolytic mechanisms to target and destroy tumor cells, thus offering a needed therapeutic alternative for refractory non-Hodgkin’s lymphoma (NHL) patients. This phase III randomized study compares the novel radioimmunotherapy yttrium-90 (90Y) ibritumomab tiuxetan with a control immunotherapy, rituximab, in 143 patients with relapsed or refractory low-grade, follicular, or transformed CD20+ transformed NHL.

PATIENTS AND METHODS: Patients received either a single intravenous (IV) dose of 90Y ibritumomab tiuxetan 0.4 mCi/kg (n = 73) or rituximab 375 mg/m2 IV weekly for four doses (n = 70). The radioimmunotherapy group was pretreated with two rituximab doses (250 mg/m2) to improve biodistribution and one dose of indium-111 ibritumomab tiuxetan for imaging and dosimetry. The primary end point, overall response rate (ORR), was assessed by an independent, blinded, lymphoma expert panel.

RESULTS: ORR was 80% for the 90Y ibritumomab tiuxetan group versus 56% for the rituximab group (P = .002). Complete response (CR) rates were 30% and 16% in the 90Y ibritumomab tiuxetan and rituximab groups, respectively (P = .04). An additional 4% achieved an unconfirmed CR in each group. Kaplan-Meier estimated median duration of response was 14.2 months in the 90Y ibritumomab tiuxetan group versus 12.1 months in the control group (P = .6), and time to progression was 11.2 versus 10.1 months (P = .173) in all patients. Durable responses of >= 6 months were 64% versus 47% (P = .030). Reversible myelosuppression was the primary toxicity noted with 90Y ibritumomab tiuxetan.

CONCLUSION: Radioimmunotherapy with 90Y ibritumomab tiuxetan is well tolerated and produces statistically and clinically significant higher ORR and CR compared with rituximab alone.


Add to CiteULike CiteULike   Add to Complore Complore   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Facebook Facebook   Add to Reddit Reddit   Add to Technorati Technorati   Add to Twitter Twitter    What's this?


This article has been cited by other articles:


Home page
 JCOHome page
T. E. Witzig, P. H. Wiernik, T. Moore, C. Reeder, C. Cole, G. Justice, H. Kaplan, M. Voralia, D. Pietronigro, K. Takeshita, et al.
Lenalidomide Oral Monotherapy Produces Durable Responses in Relapsed or Refractory Indolent Non-Hodgkin's Lymphoma
J. Clin. Oncol., November 10, 2009; 27(32): 5404 - 5409.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
A. M. Evens, W. G. Spies, I. B. Helenowski, D. Patton, S. Spies, B. D. Jovanovic, S. Miyata, E. Hamilton, D. Variakojis, J. Chen, et al.
The Novel Expanded Porphyrin, Motexafin Gadolinium, Combined with [90Y]Ibritumomab Tiuxetan for Relapsed/Refractory Non-Hodgkin's Lymphoma: Preclinical Findings and Results of a Phase I Trial
Clin. Cancer Res., October 15, 2009; 15(20): 6462 - 6471.
[Abstract] [Full Text] [PDF]

Home page
 The OncologistHome page
S. A. Gregory, K. Hohloch, C. Gisselbrecht, K. Tobinai, and M. Dreyling
Harnessing the Energy: Development of Radioimmunotherapy for Patients with Non-Hodgkin's Lymphoma
Oncologist, October 1, 2009; 14(suppl_2): 4 - 16.
[Abstract] [Full Text] [PDF]

Home page
 The OncologistHome page
F. Morschhauser, M. Dreyling, A. Rohatiner, F. Hagemeister, and A. Bischof Delaloye
Rationale for Consolidation to Improve Progression-Free Survival in Patients with Non-Hodgkin's Lymphoma: A Review of the Evidence
Oncologist, October 1, 2009; 14(suppl_2): 17 - 29.
[Abstract] [Full Text] [PDF]

Home page
 BloodHome page
M. Di Mascio, C. H. Paik, J. A. Carrasquillo, J.-S. Maeng, B.-S. Jang, I. S. Shin, S. Srinivasula, R. Byrum, A. Neria, W. Kopp, et al.
Noninvasive in vivo imaging of CD4 cells in simian-human immunodeficiency virus (SHIV)-infected nonhuman primates
Blood, July 9, 2009; 114(2): 328 - 337.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
A. Freedman, S. S. Neelapu, C. Nichols, M. J. Robertson, B. Djulbegovic, J. N. Winter, J. F. Bender, D. P. Gold, R. G. Ghalie, M. E. Stewart, et al.
Placebo-Controlled Phase III Trial of Patient-Specific Immunotherapy With Mitumprotimut-T and Granulocyte-Macrophage Colony-Stimulating Factor After Rituximab in Patients With Follicular Lymphoma
J. Clin. Oncol., June 20, 2009; 27(18): 3036 - 3043.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
A. M. Al-Katib, A. Aboukameel, R. Mohammad, M.-C. Bissery, and C. Zuany-Amorim
Superior Antitumor Activity of SAR3419 to Rituximab in Xenograft Models for Non-Hodgkin's Lymphoma
Clin. Cancer Res., June 15, 2009; 15(12): 4038 - 4045.
[Abstract] [Full Text] [PDF]

Home page
 BloodHome page
R. M. Sharkey, O. W. Press, and D. M. Goldenberg
A re-examination of radioimmunotherapy in the treatment of non-Hodgkin lymphoma: prospects for dual-targeted antibody/radioantibody therapy
Blood, April 23, 2009; 113(17): 3891 - 3895.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
S. Shibata, A. Raubitschek, L. Leong, M. Koczywas, L. Williams, J. Zhan, and J. Y.C. Wong
A Phase I Study of a Combination of Yttrium-90-Labeled Anti-Carcinoembryonic Antigen (CEA) Antibody and Gemcitabine in Patients with CEA-Producing Advanced Malignancies
Clin. Cancer Res., April 15, 2009; 15(8): 2935 - 2941.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
J. N. Winter, D. J. Inwards, S. Spies, G. Wiseman, D. Patton, W. Erwin, A. W. Rademaker, B. B. Weitner, S. F. Williams, M. S. Tallman, et al.
Yttrium-90 Ibritumomab Tiuxetan Doses Calculated to Deliver up to 15 Gy to Critical Organs May Be Safely Combined With High-Dose BEAM and Autologous Transplantation in Relapsed or Refractory B-Cell Non-Hodgkin's Lymphoma
J. Clin. Oncol., April 1, 2009; 27(10): 1653 - 1659.
[Abstract] [Full Text] [PDF]

Home page
 JNMHome page
R. M. Sharkey, H. Karacay, C. R. Johnson, S. Litwin, E. A. Rossi, W. J. McBride, C.-H. Chang, and D. M. Goldenberg
Pretargeted Versus Directly Targeted Radioimmunotherapy Combined with Anti-CD20 Antibody Consolidation Therapy of Non-Hodgkin Lymphoma
J. Nucl. Med., March 1, 2009; 50(3): 444 - 453.
[Abstract] [Full Text] [PDF]

Home page
 BloodHome page
T. M. Illidge, M. Bayne, N. S. Brown, S. Chilton, M. S. Cragg, M. J. Glennie, Y. Du, V. Lewington, J. Smart, J. Thom, et al.
Phase 1/2 study of fractionated 131I-rituximab in low-grade B-cell lymphoma: the effect of prior rituximab dosing and tumor burden on subsequent radioimmunotherapy
Blood, February 12, 2009; 113(7): 1412 - 1421.
[Abstract] [Full Text] [PDF]

Home page
 Neuro Oncol DukeHome page
S. Maza, P. Kiewe, D. L. Munz, A. Korfel, B. Hamm, K. Jahnke, and E. Thiel
First report on a prospective trial with yttrium-90-labeled ibritumomab tiuxetan (Zevalin) in primary CNS lymphoma
Neuro-oncol, January 1, 2009; 11(4): 423 - 429.
[Abstract] [Full Text] [PDF]

Home page
 JNMHome page
H. A. Jacene, R. Filice, W. Kasecamp, and R. L. Wahl
18F-FDG PET/CT for Monitoring the Response of Lymphoma to Radioimmunotherapy
J. Nucl. Med., January 1, 2009; 50(1): 8 - 17.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
F. Morschhauser, J. Radford, A. Van Hoof, U. Vitolo, P. Soubeyran, H. Tilly, P. C. Huijgens, A. Kolstad, F. d'Amore, M. G. Diaz, et al.
Phase III Trial of Consolidation Therapy With Yttrium-90-Ibritumomab Tiuxetan Compared With No Additional Therapy After First Remission in Advanced Follicular Lymphoma
J. Clin. Oncol., November 10, 2008; 26(32): 5156 - 5164.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
O. W. Press
Evidence Mounts for the Efficacy of Radioimmunotherapy for B-Cell Lymphomas
J. Clin. Oncol., November 10, 2008; 26(32): 5147 - 5150.
[Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
S. A. Jacobs, S. H. Swerdlow, J. Kant, K. A. Foon, R. Jankowitz, S. R. Land, N. DeMonaco, J. Joyce, J. L. Osborn, T. L. Evans, et al.
Phase II Trial of Short-Course CHOP-R Followed by 90Y-ibritumomab Tiuxetan and Extended Rituximab in Previously Untreated Follicular Lymphoma
Clin. Cancer Res., November 1, 2008; 14(21): 7088 - 7094.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
E. Racila, B. K. Link, W.-K. Weng, T. E. Witzig, S. Ansell, M. J. Maurer, J. Huang, C. Dahle, A. Halwani, R. Levy, et al.
A Polymorphism in the Complement Component C1qA Correlates with Prolonged Response Following Rituximab Therapy of Follicular Lymphoma
Clin. Cancer Res., October 15, 2008; 14(20): 6697 - 6703.
[Abstract] [Full Text] [PDF]

Home page
 BloodHome page
T. W. Speer
Fully human monoclonal antibodies and targeted radionuclide therapy
Blood, September 15, 2008; 112(6): 2584 - 2585.
[Full Text] [PDF]

Home page
 CA Cancer J ClinHome page
M. Bendandi
Aiming at a Curative Strategy for Follicular Lymphoma
CA Cancer J Clin, September 1, 2008; 58(5): 305 - 317.
[Abstract] [Full Text] [PDF]

Home page
 NEJMHome page
B. D. Cheson and J. P. Leonard
Monoclonal Antibody Therapy for B-Cell Non-Hodgkin's Lymphoma
N. Engl. J. Med., August 7, 2008; 359(6): 613 - 626.
[Full Text] [PDF]

Home page
 Cancer Res.Home page
R. M. Sharkey, H. Karacay, S. Litwin, E. A. Rossi, W. J. McBride, C.-H. Chang, and D. M. Goldenberg
Improved Therapeutic Results by Pretargeted Radioimmunotherapy of Non-Hodgkin's Lymphoma with a New Recombinant, Trivalent, Anti-CD20, Bispecific Antibody
Cancer Res., July 1, 2008; 68(13): 5282 - 5290.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
M. Ychou, D. Azria, C. Menkarios, P. Faurous, F. Quenet, B. Saint-Aubert, P. Rouanet, M. Pelegrin, C. Bascoul-Mollevi, D. Guerreau, et al.
Adjuvant Radioimmunotherapy Trial with Iodine-131-Labeled Anti-Carcinoembryonic Antigen Monoclonal Antibody F6 F(ab')2 after Resection of Liver Metastases from Colorectal Cancer
Clin. Cancer Res., June 1, 2008; 14(11): 3487 - 3493.
[Abstract] [Full Text] [PDF]

Home page
 The OncologistHome page
F. Buchegger, O. W. Press, A. B. Delaloye, and N. Ketterer
Radiolabeled and Native Antibodies and the Prospect of Cure of Follicular Lymphoma
Oncologist, June 1, 2008; 13(6): 657 - 667.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
E. F. Fidarova, E. El-Emir, G. M. Boxer, U. Qureshi, J. L.J. Dearling, M. P. Robson, R. H.J. Begent, K. R. Trott, and R. B. Pedley
Microdistribution of Targeted, Fluorescently Labeled Anti-Carcinoembryonic Antigen Antibody in Metastatic Colorectal Cancer: Implications for Radioimmunotherapy
Clin. Cancer Res., May 1, 2008; 14(9): 2639 - 2646.
[Abstract] [Full Text] [PDF]

Home page
 haematolHome page
C. Bodet-Milin, F. Kraeber-Bodere, B. Dupas, F. Morschhauser, T. Gastinne, S. Le Gouill, L. Campion, J.-L. Harousseau, W. A. Wegener, D. M. Goldenberg, et al.
Evaluation of response to fractionated radioimmunotherapy with 90Y-epratuzumab in non-Hodgkin's lymphoma by 18F-fluorodeoxyglucose positron emission tomography
Haematologica, March 1, 2008; 93(3): 390 - 397.
[Abstract] [Full Text] [PDF]

Home page
 RadiologyHome page
G. A. Ulaner, P. M. Colletti, and P. S. Conti
B-Cell Non-Hodgkin Lymphoma: PET/CT Evaluation after 90Y-Ibritumomab Tiuxetan Radioimmunotherapy--Initial Experience
Radiology, March 1, 2008; 246(3): 895 - 902.
[Abstract] [Full Text] [PDF]

Home page
 JNMHome page
A. Khaibullina, B.-S. Jang, H. Sun, N. Le, S. Yu, V. Frenkel, J. A. Carrasquillo, I. Pastan, K. C.P. Li, and C. H. Paik
Pulsed High-Intensity Focused Ultrasound Enhances Uptake of Radiolabeled Monoclonal Antibody to Human Epidermoid Tumor in Nude Mice
J. Nucl. Med., February 1, 2008; 49(2): 295 - 302.
[Abstract] [Full Text] [PDF]

Home page
 JNMHome page
M. Cremonesi, M. Ferrari, C. M. Grana, A. Vanazzi, M. Stabin, M. Bartolomei, S. Papi, G. Prisco, G. Martinelli, G. Paganelli, et al.
High-Dose Radioimmunotherapy with 90Y-Ibritumomab Tiuxetan: Comparative Dosimetric Study for Tailored Treatment
J. Nucl. Med., November 1, 2007; 48(11): 1871 - 1879.
[Abstract] [Full Text] [PDF]

Home page
 Ann OncolHome page
W. J. G. Oyen, L. Bodei, F. Giammarile, H. R. Maecke, J. Tennvall, M. Luster, and B. Brans
Targeted therapy in nuclear medicine current status and future prospects
Ann. Onc., November 1, 2007; 18(11): 1782 - 1792.
[Abstract] [Full Text] [PDF]

Home page
 JNMHome page
H. A. Jacene, R. Filice, W. Kasecamp, and R. L. Wahl
Comparison of 90Y-Ibritumomab Tiuxetan and 131I-Tositumomab in Clinical Practice
J. Nucl. Med., November 1, 2007; 48(11): 1767 - 1776.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
M. S. Czuczman, C. Emmanouilides, M. Darif, T. E. Witzig, L. I. Gordon, S. Revell, K. Vo, and A. Molina
Treatment-Related Myelodysplastic Syndrome and Acute Myelogenous Leukemia in Patients Treated With Ibritumomab Tiuxetan Radioimmunotherapy
J. Clin. Oncol., September 20, 2007; 25(27): 4285 - 4292.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
D. J. Green, J. M. Pagel, A. Pantelias, N. Hedin, Y. Lin, D. S. Wilbur, A. Gopal, D. K. Hamlin, and O. W. Press
Pretargeted Radioimmunotherapy for B-Cell Lymphomas
Clin. Cancer Res., September 15, 2007; 13(18): 5598s - 5603s.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
R. Balhorn, S. Hok, P. A. Burke, F. C. Lightstone, M. Cosman, A. Zemla, G. Mirick, J. Perkins, A. Natarajan, M. Corzett, et al.
Selective High-Affinity Ligand Antibody Mimics for Cancer Diagnosis and Therapy: Initial Application to Lymphoma/Leukemia
Clin. Cancer Res., September 15, 2007; 13(18): 5621s - 5628s.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
P. Martin, R. R. Furman, M. Coleman, and J. P. Leonard
Phase I to III Trials of Anti B Cell Therapy in Non Hodgkin's Lymphoma
Clin. Cancer Res., September 15, 2007; 13(18): 5636s - 5642s.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
E. Cooney-Qualter, M. Krailo, A. Angiolillo, R. A. Fawwaz, G. Wiseman, L. Harrison, V. Kohl, P. C. Adamson, J. Ayello, C. vande Ven, et al.
A Phase I Study of 90Yttrium-Ibritumomab-Tiuxetan in Children and Adolescents with Relapsed/Refractory CD20-Positive Non Hodgkin's Lymphoma: A Children's Oncology Group Study
Clin. Cancer Res., September 15, 2007; 13(18): 5652s - 5660s.
[Abstract] [Full Text] [PDF]

Home page
 BloodHome page
F. Morschhauser, T. Illidge, D. Huglo, G. Martinelli, G. Paganelli, P. L. Zinzani, S. Rule, A. M. Liberati, N. Milpied, G. Hess, et al.
Efficacy and safety of yttrium-90 ibritumomab tiuxetan in patients with relapsed or refractory diffuse large B-cell lymphoma not appropriate for autologous stem-cell transplantation
Blood, July 1, 2007; 110(1): 54 - 58.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
J. M. Pagel, A. Pantelias, N. Hedin, S. Wilbur, L. Saganic, Y. Lin, D. Axworthy, D. K. Hamlin, D. S. Wilbur, A. K. Gopal, et al.
Evaluation of CD20, CD22, and HLA-DR Targeting for Radioimmunotherapy of B-Cell Lymphomas
Cancer Res., June 15, 2007; 67(12): 5921 - 5928.
[Abstract] [Full Text] [PDF]

Home page
 BloodHome page
A. Pantelias, J. M. Pagel, N. Hedin, L. Saganic, S. Wilbur, D. K. Hamlin, D. S. Wilbur, Y. Lin, D. Stone, D. Axworthy, et al.
Comparative biodistributions of pretargeted radioimmunoconjugates targeting CD20, CD22, and DR molecules on human B-cell lymphomas
Blood, June 1, 2007; 109(11): 4980 - 4987.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
V. Tolmachev, A. Orlova, R. Pehrson, J. Galli, B. Baastrup, K. Andersson, M. Sandstrom, D. Rosik, J. Carlsson, H. Lundqvist, et al.
Radionuclide Therapy of HER2-Positive Microxenografts Using a 177Lu-Labeled HER2-Specific Affibody Molecule
Cancer Res., March 15, 2007; 67(6): 2773 - 2782.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
K. Knogler, J. Grunberg, K. Zimmermann, S. Cohrs, M. Honer, S. Ametamey, P. Altevogt, M. Fogel, P. A. Schubiger, and I. Novak-Hofer
Copper-67 Radioimmunotherapy and Growth Inhibition by Anti-L1-Cell Adhesion Molecule Monoclonal Antibodies in a Therapy Model of Ovarian Cancer Metastasis
Clin. Cancer Res., January 15, 2007; 13(2): 603 - 611.
[Abstract] [Full Text] [PDF]

Home page
 JNMHome page
H. Song, Y. Du, G. Sgouros, A. Prideaux, E. Frey, and R. L. Wahl
Therapeutic Potential of 90Y- and 131I-Labeled Anti-CD20 Monoclonal Antibody in Treating Non-Hodgkin's Lymphoma with Pulmonary Involvement: A Monte Carlo-Based Dosimetric Analysis
J. Nucl. Med., January 1, 2007; 48(1): 150 - 157.
[Abstract] [Full Text] [PDF]

Home page
 JNMHome page
D. M. Goldenberg
Adjuvant and Combined Radioimmunotherapy: Problems and Prospects on the Road to Minerva
J. Nucl. Med., November 1, 2006; 47(11): 1746 - 1748.
[Full Text] [PDF]

Home page
 JCOHome page
M. F. Leahy, J. F. Seymour, R. J. Hicks, and J. H. Turner
Multicenter Phase II Clinical Study of Iodine-131-Rituximab Radioimmunotherapy in Relapsed or Refractory Indolent Non-Hodgkin's Lymphoma
J. Clin. Oncol., September 20, 2006; 24(27): 4418 - 4425.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
O. W. Press, J. M. Unger, R. M. Braziel, D. G. Maloney, T. P. Miller, M. LeBlanc, and R. I. Fisher
Phase II Trial of CHOP Chemotherapy Followed by Tositumomab/Iodine I-131 Tositumomab for Previously Untreated Follicular Non-Hodgkin's Lymphoma: Five-Year Follow-Up of Southwest Oncology Group Protocol S9911
J. Clin. Oncol., September 1, 2006; 24(25): 4143 - 4149.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
S. J. Strauss, F. Morschhauser, J. Rech, R. Repp, P. Solal-Celigny, P. L. Zinzani, A. Engert, B. Coiffier, D. F. Hoelzer, W. A. Wegener, et al.
Multicenter Phase II Trial of Immunotherapy With the Humanized Anti-CD22 Antibody, Epratuzumab, in Combination With Rituximab, in Refractory or Recurrent Non-Hodgkin's Lymphoma
J. Clin. Oncol., August 20, 2006; 24(24): 3880 - 3886.
[Abstract] [Full Text] [PDF]

Home page
 CA Cancer J ClinHome page
R. M. Sharkey and D. M. Goldenberg
Targeted Therapy of Cancer: New Prospects for Antibodies and Immunoconjugates
CA Cancer J Clin, July 1, 2006; 56(4): 226 - 243.
[Abstract] [Full Text] [PDF]

Home page
 BloodHome page
J. M. Pagel, Y. Lin, N. Hedin, A. Pantelias, D. Axworthy, D. Stone, D. K. Hamlin, D. S. Wilbur, and O. W. Press
Comparison of a tetravalent single-chain antibody-streptavidin fusion protein and an antibody-streptavidin chemical conjugate for pretargeted anti-CD20 radioimmunotherapy of B-cell lymphomas
Blood, July 1, 2006; 108(1): 328 - 336.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
D. M. Goldenberg, R. M. Sharkey, G. Paganelli, J. Barbet, and J.-F. Chatal
Antibody Pretargeting Advances Cancer Radioimmunodetection and Radioimmunotherapy
J. Clin. Oncol., February 10, 2006; 24(5): 823 - 834.
[Abstract] [Full Text] [PDF]

Home page
 JNMHome page
R. M. Reilly
Radioimmunotherapy of Solid Tumors: The Promise of Pretargeting Strategies Using Bispecific Antibodies and Radiolabeled Haptens
J. Nucl. Med., February 1, 2006; 47(2): 196 - 199.
[Full Text] [PDF]

Home page
 J. Biol. Chem.Home page
S. M. Glaser, I. E. Hughes, J. R. Hopp, K. Hathaway, D. Perret, and M. E. Reff
Novel Antibody Hinge Regions for Efficient Production of CH2 Domain-deleted Antibodies
J. Biol. Chem., December 16, 2005; 280(50): 41494 - 41503.
[Abstract] [Full Text] [PDF]

Home page
 BloodHome page
W. Hiddemann, M. Kneba, M. Dreyling, N. Schmitz, E. Lengfelder, R. Schmits, M. Reiser, B. Metzner, H. Harder, S. Hegewisch-Becker, et al.
Frontline therapy with rituximab added to the combination of cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) significantly improves the outcome for patients with advanced-stage follicular lymphoma compared with therapy with CHOP alone: results of a prospective randomized study of the German Low-Grade Lymphoma Study Group
Blood, December 1, 2005; 106(12): 3725 - 3732.
[Abstract] [Full Text] [PDF]

Home page
 JNMHome page
P. S. Conti, C. White, P. Pieslor, A. Molina, J. Aussie, and P. Foster
The Role of Imaging with 111In-Ibritumomab Tiuxetan in the Ibritumomab Tiuxetan (Zevalin) Regimen: Results from a Zevalin Imaging Registry
J. Nucl. Med., November 1, 2005; 46(11): 1812 - 1818.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
M. S. Kaminski, J. A. Radford, S. A. Gregory, J. P. Leonard, S. J. Knox, S. Kroll, and R. L. Wahl
Re-Treatment With I-131 Tositumomab in Patients With Non-Hodgkin's Lymphoma Who Had Previously Responded to I-131 Tositumomab
J. Clin. Oncol., November 1, 2005; 23(31): 7985 - 7993.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
R. I. Fisher, M. S. Kaminski, R. L. Wahl, S. J. Knox, A. D. Zelenetz, J. M. Vose, J. P. Leonard, S. Kroll, S. J. Goldsmith, and M. Coleman
Tositumomab and Iodine-131 Tositumomab Produces Durable Complete Remissions in a Subset of Heavily Pretreated Patients With Low-Grade and Transformed Non-Hodgkin's Lymphomas
J. Clin. Oncol., October 20, 2005; 23(30): 7565 - 7573.
[Abstract] [Full Text] [PDF]

Home page
 BloodHome page
A. Nademanee, S. Forman, A. Molina, H. Fung, D. Smith, A. Dagis, C. Kwok, D. Yamauchi, A.-L. Anderson, P. Falk, et al.
A phase 1/2 trial of high-dose yttrium-90-ibritumomab tiuxetan in combination with high-dose etoposide and cyclophosphamide followed by autologous stem cell transplantation in patients with poor-risk or relapsed non-Hodgkin lymphoma
Blood, October 15, 2005; 106(8): 2896 - 2902.
[Abstract] [Full Text] [PDF]

Home page
 Ann OncolHome page
P. F. Ferrucci, A. Vanazzi, G. Tesoriere, M. Ferrari, M. Bartolomei, P. Rocca, M. Cremonesi, G. Paganelli, and G. Martinelli
Cerebrospinal fluid diffusion of Zevalin(R) after high-activity treatment and stem cell support in a patient affected by diffuse large B-cell non-Hodgkin's lymphoma with central nervous system involvement
Ann. Onc., October 1, 2005; 16(10): 1710 - 1711.
[Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
D. M. Goldenberg
Introduction to the Tenth Conference on Cancer Therapy with Antibodies and Immunoconjugates
Clin. Cancer Res., October 1, 2005; 11(19): 7045s - 7046s.
[Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
G. L. DeNardo, E. Tobin, K. Chan, B. M. Bradt, and S. J. DeNardo
Direct Antilymphoma Effects on Human Lymphoma Cells of Monotherapy and Combination Therapy with CD20 and HLA-DR Antibodies and 90Y-Labeled HLA-DR Antibodies
Clin. Cancer Res., October 1, 2005; 11(19): 7075s - 7079s.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
S. A. Jacobs, N. Vidnovic, J. Joyce, B. McCook, F. Torok, and N. Avril
Full-Dose 90Y Ibritumomab Tiuxetan Therapy Is Safe in Patients with Prior Myeloablative Chemotherapy
Clin. Cancer Res., October 1, 2005; 11(19): 7146s - 7150s.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
W. Hiddemann, C. Buske, M. Dreyling, O. Weigert, G. Lenz, R. Forstpointner, C. Nickenig, and M. Unterhalt
Treatment Strategies in Follicular Lymphomas: Current Status and Future Perspectives
J. Clin. Oncol., September 10, 2005; 23(26): 6394 - 6399.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
J. P. Leonard, M. Coleman, L. Kostakoglu, A. Chadburn, E. Cesarman, R. R. Furman, M. W. Schuster, R. Niesvizky, D. Muss, J. Fiore, et al.
Abbreviated Chemotherapy With Fludarabine Followed by Tositumomab and Iodine I 131 Tositumomab for Untreated Follicular Lymphoma
J. Clin. Oncol., August 20, 2005; 23(24): 5696 - 5704.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
J. P. Leonard, M. Coleman, J. Ketas, M. Ashe, J. M. Fiore, R. R. Furman, R. Niesvizky, T. Shore, A. Chadburn, H. Horne, et al.
Combination Antibody Therapy With Epratuzumab and Rituximab in Relapsed or Refractory Non-Hodgkin's Lymphoma
J. Clin. Oncol., August 1, 2005; 23(22): 5044 - 5051.
[Abstract] [Full Text] [PDF]

Home page
 Clin Med ResHome page
A. V. Rao, G. Akabani, and D. A. Rizzieri
Radioimmunotherapy for Non-Hodgkin's Lymphoma
Clin. Med. Res., August 1, 2005; 3(3): 157 - 165.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
O. Linden, C. Hindorf, E. Cavallin-Stahl, W. A. Wegener, D. M. Goldenberg, H. Horne, T. Ohlsson, L. Stenberg, S.-E. Strand, and J. Tennvall
Dose-Fractionated Radioimmunotherapy in Non-Hodgkin's Lymphoma Using DOTA-Conjugated, 90Y-Radiolabeled, Humanized Anti-CD22 Monoclonal Antibody, Epratuzumab
Clin. Cancer Res., July 15, 2005; 11(14): 5215 - 5222.
[Abstract] [Full Text] [PDF]

Home page
 BloodHome page
J. M. Bennett, M. S. Kaminski, J. P. Leonard, J. M. Vose, A. D. Zelenetz, S. J. Knox, S. Horning, O. W. Press, J. A. Radford, S. M. Kroll, et al.
Assessment of treatment-related myelodysplastic syndromes and acute myeloid leukemia in patients with non-Hodgkin lymphoma treated with tositumomab and iodine I131 tositumomab
Blood, June 15, 2005; 105(12): 4576 - 4582.
[Abstract] [Full Text] [PDF]

Home page
 Ann OncolHome page
A. Hagenbeek and V. Lewington
Report of a European consensus workshop to develop recommendations for the optimal use of 90Y-ibritumomab tiuxetan (Zevalin(R)) in lymphoma
Ann. Onc., May 1, 2005; 16(5): 786 - 792.
[Abstract] [Full Text] [PDF]

Home page
 JRSMHome page
A. P Levene, G. Singh, and C. Palmieri
Therapeutic monoclonal antibodies in oncology
J R Soc Med, April 1, 2005; 98(4): 146 - 152.
[Full Text] [PDF]

Home page
 JCOHome page
J. D. Hainsworth, S. Litchy, D. W. Shaffer, V. L. Lackey, M. Grimaldi, and F. A. Greco
Maximizing Therapeutic Benefit of Rituximab: Maintenance Therapy Versus Re-Treatment at Progression in Patients With Indolent Non-Hodgkin's Lymphoma--A Randomized Phase II Trial of the Minnie Pearl Cancer Research Network
J. Clin. Oncol., February 20, 2005; 23(6): 1088 - 1095.
[Abstract] [Full Text] [PDF]

Home page
 NEJMHome page
J. M. Connors
Radioimmunotherapy -- Hot New Treatment for Lymphoma
N. Engl. J. Med., February 3, 2005; 352(5): 496 - 498.
[Full Text] [PDF]

Home page
 JNMHome page
D. M. Goldenberg and R. M. Sharkey
Radioimmunotherapy of Non-Hodgkin's Lymphoma Revisited
J. Nucl. Med., February 1, 2005; 46(2): 383 - 384.
[Full Text] [PDF]

Home page
 JCOHome page
S. J. Horning, A. Younes, V. Jain, S. Kroll, J. Lucas, D. Podoloff, and M. Goris
Efficacy and Safety of Tositumomab and Iodine-131 Tositumomab (Bexxar) in B-Cell Lymphoma, Progressive After Rituximab
J. Clin. Oncol., February 1, 2005; 23(4): 712 - 719.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
M. Ginj, J. Chen, M. A. Walter, V. Eltschinger, J. C. Reubi, and H. R. Maecke
Preclinical Evaluation of New and Highly Potent Analogues of Octreotide for Predictive Imaging and Targeted Radiotherapy
Clin. Cancer Res., February 1, 2005; 11(3): 1136 - 1145.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
E. R. Nemecek, D. K. Hamlin, D. R. Fisher, K. A. Krohn, J. M. Pagel, F. R. Appelbaum, O. W. Press, and D. C. Matthews
Biodistribution of Yttrium-90-Labeled Anti-CD45 Antibody in a Nonhuman Primate Model
Clin. Cancer Res., January 15, 2005; 11(2): 787 - 794.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
M. Z. Lin, M. A. Teitell, and G. J. Schiller
The Evolution of Antibodies into Versatile Tumor-Targeting Agents
Clin. Cancer Res., January 1, 2005; 11(1): 129 - 138.
[Abstract] [Full Text] [PDF]

Home page
 ASH Education BookHome page
A. S. Freedman
Biology and Management of Histologic Transformation of Indolent Lymphoma
Hematology, January 1, 2005; 2005(1): 314 - 320.
[Abstract] [Full Text] [PDF]

Home page
 J. Biol. Chem.Home page
L. S. Shahied, Y. Tang, R. K. Alpaugh, R. Somer, D. Greenspon, and L. M. Weiner
Bispecific Minibodies Targeting HER2/neu and CD16 Exhibit Improved Tumor Lysis When Placed in a Divalent Tumor Antigen Binding Format
J. Biol. Chem., December 24, 2004; 279(52): 53907 - 53914.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
J. W. Friedberg
Radioimmunotherapy for Non-Hodgkin's Lymphoma
Clin. Cancer Res., December 1, 2004; 10(23): 7789 - 7791.
[Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
T. A. Davis, M. S. Kaminski, J. P. Leonard, F. J. Hsu, M. Wilkinson, A. Zelenetz, R. L. Wahl, S. Kroll, M. Coleman, M. Goris, et al.
The Radioisotope Contributes Significantly to the Activity of Radioimmunotherapy
Clin. Cancer Res., December 1, 2004; 10(23): 7792 - 7798.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
C.-L. Law, C. G. Cerveny, K. A. Gordon, K. Klussman, B. J. Mixan, D. F. Chace, D. L. Meyer, S. O. Doronina, C. B. Siegall, J. A. Francisco, et al.
Efficient Elimination of B-Lineage Lymphomas by Anti-CD20-Auristatin Conjugates
Clin. Cancer Res., December 1, 2004; 10(23): 7842 - 7851.
[Abstract] [Full Text] [PDF]

Home page
 NEJMHome page
S. S. Dave, G. Wright, B. Tan, A. Rosenwald, R. D. Gascoyne, W. C. Chan, R. I. Fisher, R. M. Braziel, L. M. Rimsza, T. M. Grogan, et al.
Prediction of Survival in Follicular Lymphoma Based on Molecular Features of Tumor-Infiltrating Immune Cells
N. Engl. J. Med., November 18, 2004; 351(21): 2159 - 2169.
[Abstract] [Full Text] [PDF]

Home page
 Molecular Cancer TherapeuticsHome page
J. Christiansen and A. K. Rajasekaran
Biological impediments to monoclonal antibody-based cancer immunotherapy
Mol. Cancer Ther., November 1, 2004; 3(11): 1493 - 1501.
[Abstract] [Full Text] [PDF]

Home page
 Integr Cancer TherHome page
S. Hallmeyer and D. Peace
Integrative Tumor Board: Recurrent Lymphoma
Integr Cancer Ther, September 1, 2004; 3(3): 239 - 243.
[PDF]

Home page
 CA Cancer J ClinHome page
B. D. Cheson
What Is New in Lymphoma?
CA Cancer J Clin, September 1, 2004; 54(5): 260 - 272.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
J. P. Leonard, M. Coleman, J. C. Ketas, A. Chadburn, R. Furman, M. W. Schuster, E. J. Feldman, M. Ashe, S. J. Schuster, W. A. Wegener, et al.
Epratuzumab, a Humanized Anti-CD22 Antibody, in Aggressive Non-Hodgkin's Lymphoma: Phase I/II Clinical Trial Results
Clin. Cancer Res., August 15, 2004; 10(16): 5327 - 5334.
[Abstract] [Full Text] [PDF]

Home page
 BloodHome page
A. Forero, P. L. Weiden, J. M. Vose, S. J. Knox, A. F. LoBuglio, J. Hankins, M. L. Goris, V. J. Picozzi, D. B. Axworthy, H. B. Breitz, et al.
Phase 1 trial of a novel anti-CD20 fusion protein in pretargeted radioimmunotherapy for B-cell non-Hodgkin lymphoma
Blood, July 1, 2004; 104(1): 227 - 236.
[Abstract] [Full Text] [PDF]

Home page
 BloodHome page
L. I. Gordon, A. Molina, T. Witzig, C. Emmanouilides, A. Raubtischek, M. Darif, R. J. Schilder, G. Wiseman, and C. A. White
Durable responses after ibritumomab tiuxetan radioimmunotherapy for CD20+ B-cell lymphoma: long-term follow-up of a phase 1/2 study
Blood, June 15, 2004; 103(12): 4429 - 4431.
[Abstract] [Full Text] [PDF]

Home page
 Ann OncolHome page
M. Bendandi, S. A. Pileri, and P. L. Zinzani
Challenging paradigms in lymphoma treatment
Ann. Onc., May 1, 2004; 15(5): 703 - 711.
[Full Text] [PDF]

Home page
 JCOHome page
A.J. Davies, A.Z.S. Rohatiner, S. Howell, K.E. Britton, S.E. Owens, I.N. Micallef, D.P. Deakin, B.M. Carrington, J.A. Lawrance, S. Vinnicombe, et al.
Tositumomab and Iodine I 131 Tositumomab for Recurrent Indolent and Transformed B-Cell Non-Hodgkin's Lymphoma
J. Clin. Oncol., April 15, 2004; 22(8): 1469 - 1479.
[Abstract] [Full Text] [PDF]

Home page
 BloodHome page
Y. Du, J. Honeychurch, M. S. Cragg, M. Bayne, M. J. Glennie, P. W. M. Johnson, and T. M. Illidge
Antibody-induced intracellular signaling works in combination with radiation to eradicate lymphoma in radioimmunotherapy
Blood, February 15, 2004; 103(4): 1485 - 1494.
[Abstract] [Full Text] [PDF]

Home page
 ASH Education BookHome page
J. N. Winter, R. D. Gascoyne, and K. Van Besien
Low-Grade Lymphoma
Hematology, January 1, 2004; 2004(1): 203 - 220.
[Abstract] [Full Text] [PDF]

Home page
 JNMHome page
R. M. Sharkey, A. Brenner, J. Burton, G. Hajjar, S. P. Toder, A. Alavi, A. Matthies, D. E. Tsai, S. J. Schuster, E. A. Stadtmauer, et al.
Radioimmunotherapy of Non-Hodgkin's Lymphoma with 90Y-DOTA Humanized Anti-CD22 IgG (90Y-Epratuzumab): Do Tumor Targeting and Dosimetry Predict Therapeutic Response?
J. Nucl. Med., December 1, 2003; 44(12): 2000 - 2018.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
J. Y. C. Wong, S. Shibata, L. E. Williams, C. S. Kwok, A. Liu, D. Z. Chu, D. M. Yamauchi, S. Wilczynski, D. N. Ikle, A. M. Wu, et al.
A Phase I Trial of 90Y-Anti-Carcinoembryonic Antigen Chimeric T84.66 Radioimmunotherapy with 5-Fluorouracil in Patients with Metastatic Colorectal Cancer
Clin. Cancer Res., December 1, 2003; 9(16): 5842 - 5852.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
T. A. Lister
High-Dose Therapy for Follicular Lymphoma Revisited: Not If, but When?
J. Clin. Oncol., November 1, 2003; 21(21): 3894 - 3896.
[Full Text] [PDF]

Home page
 Cancer Res.Home page
V. Bhaskar, D. A. Law, E. Ibsen, D. Breinberg, K. M. Cass, R. B. DuBridge, F. Evangelista, S. M. Henshall, P. Hevezi, J. C. Miller, et al.
E-Selectin Up-Regulation Allows for Targeted Drug Delivery in Prostate Cancer
Cancer Res., October 1, 2003; 63(19): 6387 - 6394.
[Abstract] [Full Text] [PDF]

Home page
 BloodHome page
A. K. Gopal, T. A. Gooley, D. G. Maloney, S. H. Petersdorf, J. F. Eary, J. G. Rajendran, S. A. Bush, L. D. Durack, J. Golden, P. J. Martin, et al.
High-dose radioimmunotherapy versus conventional high-dose therapy and autologous hematopoietic stem cell transplantation for relapsed follicular non-Hodgkin lymphoma: a multivariable cohort analysis
Blood, October 1, 2003; 102(7): 2351 - 2357.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
P. K. E. Borjesson, E. J. Postema, J. C. Roos, D. R. Colnot, H. A. M. Marres, M. H. van Schie, G. Stehle, R. de Bree, G. B. Snow, W. J. G. Oyen, et al.
Phase I Therapy Study with 186Re-labeled Humanized Monoclonal Antibody BIWA 4 (Bivatuzumab) in Patients with Head and Neck Squamous Cell Carcinoma
Clin. Cancer Res., September 1, 2003; 9(10): 3961s - 3972s.
[Abstract] [Full Text]


About
JCO		 Editorial
Roster		 Advertising
Information		 Librarians &
Institutions		 Rights &
Permissions		 PDA Services

Copyright © 2002 by the American Society of Clinical Oncology, Online ISSN: 1527-7755. Print ISSN: 0732-183X
Terms and Conditions of Use
  HighWire Press HighWire Press™ assists in the publication of JCO Online